CARMAT

Availability of the 2023 Universal Registration Document

Regulatory News:

CARMAT (FR0010907956, ALCAR), designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the “Company” or “CARMAT”), today announced the publication of the Company’s Universal registration document (“URD”) for the year ended December 31, 2023.

The document, filed with the French stock-market authority (Autorité des Marchés Financiers) on April 30, 2023, is available to the public free of charge upon request, as per current legal regulations; and on the Company’s website under the section Investors / Documentation, as well as on that of the AMF (www.amf-france.org).

It notably includes the 2023 annual financial report, the report on corporate governance, the required information in relation to the share repurchase program, as well as the statutory auditor’ reports and information on the fees paid to the statutory auditor in 2023. The URD is available in French only, but for the convenience of English-speaking readers, CARMAT provides a free translation into English of its 2023 financial statements¹, which is available in the English section of its website.

●●●

About CARMAT

CARMAT is a French MedTech that designs, manufactures and markets the Aeson artificial heart. The Company’s ambition is to make Aeson the first alternative to a heart transplant, and thus provide a therapeutic solution to people suffering from end-stage biventricular heart failure, who are facing a well-known shortfall in available human grafts. The world’s first physiological artificial heart that is highly hemocompatible, pulsatile and self-regulated, Aeson could save, every year, the lives of thousands of patients waiting for a heart transplant. The device offers patients quality of life and mobility thanks to its ergonomic and portable external power supply system that is continuously connected to the implanted prosthesis. Aeson is commercially available as a bridge to transplant in the European Union and other countries that recognize CE marking. Aeson is also currently being assessed within the framework of an Early Feasibility Study (EFS) in the United States. Founded in 2008, CARMAT is based in the Paris region, with its head offices located in Vélizy-Villacoublay and its production site in Bois-d’Arcy. The Company can rely on the talent and expertise of a multidisciplinary team of circa 200 highly specialized people. CARMAT is listed on the Euronext Growth market in Paris (Ticker: ALCAR / ISIN code: FR0010907956).